Role of cyclooxygenase-2 in the angiogenesis of colorectal cancer

International Journal of Colorectal Disease

Volumn 19, Issue 1, 2004, Pages 1-11

  Rao, Milind ^a   Yang, Wenxuan ^a   Seifalian, Alexander M ^a   Winslet, Marc C ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiogenesis; Colorectal cancer; Cyclooxygenase; Cyclooxygenase inhibitor

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; ACETYLSALICYLIC ACID; BASIC FIBROBLAST GROWTH FACTOR; CANCER GROWTH FACTOR; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; ISOENZYME; MATRIX METALLOPROTEINASE; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; ROFECOXIB; SULINDAC; THROMBOXANE A2; TILMACOXIB; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADENOMATOUS POLYP; BLEEDING; CANCER GROWTH; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CARDIOVASCULAR DISEASE; COLORECTAL CANCER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; LICENSING; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN FUNCTION; REVIEW; ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS;

EID: 0347724237     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-003-0511-2     Document Type: Review

References (72)

1. Huang A, McCall JM, Weston MD, Mathur P, Quinn H, Henderson DC, et al (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89:303-310
2. Fosslien E (2001) Review: Molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis. Ann Clin Lab Sci 31:325-348
3. Le Querrec A, Duval D, Tobelem G (1993) Tumour angiogenesis. Baillieres Clin Haematol 6:711-730
4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107:1183-1188
5. Masunaga R, Kohno H, Dhar DK, Ohno S, Shibakita M, Kinugasa S, et al (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin Cancer Res 6:4064-4068
6. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, et al (1999) Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 79:1469-1477
7. Giovannucci E, Rimm. EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC (1994) Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121:241-2416
8. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609-614
9. Smalley WE, DuBois RN (1997) Colorectal cancer and nonsteroidal anti-inflammatory drugs. Adv Pharmacol 39:1-20
10. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596
11. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53:1322-1327
12. DuBois RN (2000) Review article: cyclooxygenase-a target for colon cancer prevention. Aliment Pharmacol Ther 14 [Suppl 1]:64-67
13. Chen WS, Wei SJ, Liu JM, Hsiao M, Kou-Lin J, Yang WK (2001) Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int J Cancer 91:894-899
14. Reddy BS, Hirose Y, Lubet R, Steele V, Kelloff G, Paulson S, et al (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60:293-297
15. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182-1186
16. Gately S (2000) The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 19:19-27
17. Li Z, Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, et al (2000) TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol 17:453-460
18. Matsushita M, Matsuzaki K, Date M, Watanabe T, Shibano K, Nakagawa T, et al (1999) Down-regulation of TGF-beta receptors in human colorectal cancer: implications for cancer development. Br J Cancer 80:194-205
19. Xiong B, Gong LL, Zhang F, Hu MB, Yuan HY (2002) TGF beta (1) expression and angiogenesis in colorectal cancer tissue. World J Gastroenterol 8:496-498
20. Schulze-Osthoff K, Risau W, Vollmer E, Sorg C (1990) In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 137:85-92
21. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS (2000) Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19:4611-4620
22. Vane JR, Botting RMr (2001) Therapeutic roles of selective COX-2 inhibitors. Harvey, London
23. Trifan OC, Smith RM, Thompson BD, Hla T (1999) Overexpression of cyclooxygenase-2 induces cell cycle arrest. Evidence for a prostaglandin-independent mechanism. J Biol Chem 274:34141-34147
24. Luk GD (1996) Prevention of gastrointestinal cancer-the potential role of NSAIDs in colorectal cancer. Schweiz Med Wochenschr 126:801-812
25. Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, et al (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 93:4816-8620
26. Gustafson-Svard C, Lilja I, Hallbook O, Sjodahl R (1996) Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats. Gut 38:79-84
27. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996) G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56:733-737
28. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, et al (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55:3785-9378
29. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99:2254-2259
30. Tsujii M, DuBois RN (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83:493-501
31. Crew TE, Elder DJ, Paraskeva C (2000) A cyclooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug enhances the growth inhibitory effect of butyrate in colorectal carcinoma cells expressing COX-2 protein: regulation of COX-2 by butyrate. Carcinogenesis 21:69-77
32. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58:362-636
33. Li M, Wu X, Xu XC (2001) Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 7:1010-1016
34. Elder DJ, Halton DE, Crew TE, Paraskeva C (2000) Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 86:553-560
35. Richter M, Weiss M, Weinberger I, Furstenberger G, Marian B (2001) Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 22:17-25
36. Erickson BA, Longo WE, Panesar N, Mazuski JE, Kaminski DL (1999) The effect of selective cyclooxygenase inhibitors on intestinal epithelial cell mitogenesis. J Surg Res 81:101-107
37. Fukutake M, Nakatsugi S, Isoi T, Takahashi M, Ohta T, Mamiya S, et al (1998) Suppressive effects of nimesulide, a selective inhibitor of cyclooxygenase-2, on azoxymethane-induced colon carcinogenesis in mice. Carcinogenesis 19:1939-19342
38. Ichikawa Y, Ishikawa T, Tanaka K, Togo S, Shimada H (2001) [Extracellular matrix degradation enzymes: important factors in liver metastasis of colorectal cancer and good targets for anticancer metastatic therapy]. Nippon Geka Gakkai Zasshi 102:376-380
39. Tsujii M, Kawano S, DuBois RN (1997) Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94:3336-3340
40. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
41. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al (1999) Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 187:295-301
42. Zhang H, Sun XF (2002) Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am J Gastroenterol 97:1037-1041
43. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705-716
44. Masferrer JL, Koki A, Seibert K (1999) COX-2 inhibitors. A new class of antiangiogenic agents. Ann N Y Acad Sci 889:84-86
45. Onn A, Tseng JE, Herbst RS (2001) Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin Cancer Res 7:3311-3313
46. Sheehan KM, Sheahan K, O'Donoghue DP, MacSweeney F, Conroy RM, Fitzgerald DJ, et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282:1254-1257
47. Tomozawa S, Tsuno NH, Sunami E, Hatano K, Kitayama J, Osada T, et al (2000) Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 83:324-328
48. Fujita T, Matsui M, Takaku K, Uetake H, Ichikawa W, Taketo MM, et al (1998) Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res 58:4823-4826
49. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105:1589-1594
50. Dormond O, Foletti A, Paroz C, Ruegg C (2001) NSAIDs inhibit alpha V beta 3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7:1041-1047
51. Cianchi F, Cortesini C, Bechi P, Fantappie O, Messerini L, Vannacci A, et al (2001) Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterology 121:1339-1347
52. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, et al (2001) Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 3:53-61
53. Form DM, Auerbach R (1983) PGE2 and angiogenesis. Proc Soc Exp Biol Med 172:214-218
54. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55:2556-2559
55. Levy GN (1997) Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 11:234-247
56. Bing RJ, Miyataka M, Rich KA, Hanson N, Wang X, Slosser HD, et al (2001) Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer. Clin Cancer Res 7:3385-3392
57. Daniel TO, Liu H, Morrow JD, Crews BC, Marnett LJ (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59:4574-4577
58. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, et al (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer heating. Nat Med 5:1418-1423
59. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94:252-266
60. Prescott SM, Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470:M69-M78
61. Shao J, Sheng H, Inoue H, Morrow JD, DuBois RN (2000) Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem 275:33951-3396
62. Dicker AP, Williams TL, Grant DS (2001) Targeting angiogenic processes by combination rofecoxib and ionizing radiation. Am J Clin Oncol 24:438-442
63. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62:625-631
64. Simmons DL, Botting RM, Robertson PM, Madsen ML, Vane JR (1999) Induction of an acetaminophen-sensitive cyclooxygenase with reduced sensitivity to nonsteroid antiinflammatory drugs. Proc Natl Acad Sci USA 96:3275-3280
65. Barnes CJ, Cameron IL, Hardman WE, Lee M (1998) Non-steroidol anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 77:573-580
66. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, et al (1998) Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 19:2195-2199
67. Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, et al (2002) The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32:838-846
68. Murphy VJ, Yang Z, Rorison KA, Baldwin GS (1998) Cyclooxygenase-2-selective antagonists do not inhibit growth of colorectal carcinoma cell lines. Cancer Lett 122:25-30
69. Williams CS, Watson AJ, Sheng H, Helou R, Shao J, DuBois RN (2000) Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res 60:6045-6051
70. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96:272-277
71. Whittle BJ (2000) COX-1 and COX-2 products in the gut: therapeutic impact of COX-2 inhibitors. Gut 47:320-325
72. Tomozawa S, Nagawa H, Tsuno N, Hatano K, Osada T, Kitayama J, et al (1999) Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br J Cancer 81:1274-1279